세계의 파지요법 시장

Global Phage Therapy Market to Reach US$124.8 Million by 2030

The global market for Phage Therapy estimated at US$45.3 Million in the year 2024, is expected to reach US$124.8 Million by 2030, growing at a CAGR of 18.4% over the analysis period 2024-2030. Escherichia Coli, one of the segments analyzed in the report, is expected to record a 20.4% CAGR and reach US$69.1 Million by the end of the analysis period. Growth in the Staphylococcus Aureus segment is estimated at 15.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$11.9 Million While China is Forecast to Grow at 17.3% CAGR

The Phage Therapy market in the U.S. is estimated at US$11.9 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$19.1 Million by the year 2030 trailing a CAGR of 17.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 17.2% and 15.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 13.3% CAGR.

Global Phage Therapy Market - Key Trends & Drivers Summarized

Can Bacteriophages Offer a New Frontier in the Fight Against Antibiotic Resistance?

The escalating global crisis of antibiotic resistance has placed phage therapy under the spotlight as a promising alternative for combating multidrug-resistant bacterial infections. Bacteriophages, or phages, are viruses that selectively infect and destroy bacteria, offering a highly targeted approach without disturbing beneficial microbiota. Unlike traditional antibiotics, which operate on broad-spectrum mechanisms, phages can be tailored to attack specific bacterial strains, thereby minimizing collateral damage and reducing the risk of resistance development. As antibiotic-resistant superbugs continue to threaten public health globally, the appeal of phage therapy is growing not only in clinical medicine but also in sectors like agriculture, aquaculture, and food safety. Multiple countries are now reevaluating regulatory pathways to facilitate the research and clinical integration of phage-based treatments, especially in cases where conventional antibiotics fail. Notably, compassionate use cases and individualized phage therapy have shown life-saving results in critically ill patients, further boosting interest in this technology. Academic institutions, biotech startups, and public health agencies are increasingly collaborating on global phage banks and sequencing libraries to enhance the availability and customization of phage cocktails. The specificity of phage-host interactions, while challenging, also offers a significant advantage in minimizing unintended effects on the broader ecosystem. With infectious disease control facing new hurdles in a post-antibiotic era, phage therapy is being reevaluated not as an experimental outlier but as a strategic pillar in future antimicrobial protocols.

How Is Innovation in Biotechnology Advancing the Clinical Utility of Phage Therapy?

Advancements in genetic engineering, synthetic biology, and bioinformatics are playing a pivotal role in expanding the clinical relevance of phage therapy. Today’s phage research is far more sophisticated than in earlier decades, with scientists now able to modify phages to overcome bacterial defenses, enhance lytic efficiency, and avoid immune system detection. CRISPR-Cas systems are being employed to design programmable phages capable of targeting specific resistance genes, making the therapy adaptable to a wide array of infections. Additionally, innovations in sequencing technologies and metagenomics are accelerating the identification of effective phage-bacteria pairs, significantly reducing the time required for personalized treatment planning. Encapsulation techniques and nanoformulations are also emerging to improve phage stability, bioavailability, and targeted delivery to infected tissues. The development of phage cocktails, which combine multiple phage strains, is enhancing spectrum coverage and mitigating resistance development during treatment. Biotechnology companies are working on scalable production and purification methods that meet GMP standards, addressing one of the major hurdles in bringing phage therapies to market. Clinical trials in Europe, North America, and Asia are increasingly investigating the role of phage therapy in treating infections ranging from chronic wounds to cystic fibrosis-associated pathogens. Such technological momentum is transforming phage therapy from a last-resort option into a versatile and scientifically validated modality. With the continued convergence of high-throughput lab tools and AI-driven screening systems, phage-based therapeutics are gaining credibility as a next-generation weapon in precision medicine.

What Regulatory and Infrastructure Challenges Must Be Addressed for Widespread Adoption?

Despite its potential, the widespread adoption of phage therapy faces numerous regulatory and infrastructural barriers that need urgent attention. Traditional drug approval frameworks are not well-suited to therapies that require high personalization, such as phage preparations that must be matched to a patient’s specific bacterial infection. This lack of regulatory clarity slows clinical development and discourages large-scale investment. Regulatory agencies like the FDA and EMA are gradually exploring adaptive licensing models, including compassionate use and hospital exemptions, but uniform global standards remain elusive. Manufacturing consistency, quality control, and phage characterization present additional challenges, as these biologics must be free of contaminants, genetically stable, and functionally reproducible. Another hurdle lies in the current lack of commercial-scale phage production facilities equipped to meet medical-grade standards. Many institutions still rely on in-house labs or academic setups, which limits output and quality standardization. Additionally, the scarcity of clinical professionals trained in phage therapy impedes its routine adoption in hospitals. Public perception and awareness also lag behind scientific advances, with many still viewing phage therapy as experimental or unconventional. Intellectual property constraints further complicate commercialization, as naturally occurring phages are difficult to patent, reducing the incentive for private sector investment. Cross-border collaborations and global consortia are beginning to address these gaps, but the need for dedicated policies, infrastructure upgrades, and industry-wide education remains critical. Overcoming these regulatory and logistical hurdles is essential to fully unlock the global potential of phage therapy as a mainstream medical tool.

What Forces Are Fueling Market Growth and Expanding Therapeutic Applications?

The growth in the phage therapy market is driven by several factors related to technological progress, unmet clinical needs, and evolving patient care models. One of the most significant drivers is the surge in multidrug-resistant infections, which are rendering conventional antibiotics increasingly ineffective and heightening demand for viable alternatives. Simultaneously, the advancement of genomic and proteomic tools has dramatically improved phage identification, customization, and deployment, thereby reducing developmental timelines and boosting therapeutic efficacy. The increasing incidence of chronic and hospital-acquired infections is also fueling demand for targeted antimicrobials that can circumvent traditional resistance mechanisms. On the end-user side, hospitals and specialized infection clinics are beginning to incorporate phage therapy for difficult-to-treat cases, supported by growing evidence from pilot programs and case studies. Biopharmaceutical companies and academic research centers are investing heavily in the creation of phage libraries, predictive modeling software, and scalable manufacturing systems to broaden therapeutic availability. Government and non-profit funding initiatives focused on combating antibiotic resistance are providing critical financial support for R&D in this space. Consumer behavior is also playing a role, with patients increasingly advocating for alternative therapies and personalized medicine approaches that go beyond traditional pharmaceuticals. Additionally, veterinary medicine, agriculture, and aquaculture are emerging as strong application areas where phage-based solutions are being used to reduce antibiotic dependency and improve microbial control. All these factors, combined with an intensifying global focus on infectious disease resilience and healthcare innovation, are positioning phage therapy as a high-potential, multidisciplinary growth sector for the foreseeable future.

SCOPE OF STUDY:

The report analyzes the Phage Therapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Escherichia Coli, Staphylococcus Aureus, Salmonella, Other Products); Application (Animal Health Application, Food Application, Other Applications)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 47 Featured) -

• Adaptive Phage Therapeutics
• Armata Pharmaceuticals
• BiomX Ltd.
• C3J Therapeutics
• CYTOBIOTICS Inc.
• Eligo Bioscience
• EnBiotix, Inc.
• InnoPhage Ltd.
• Intralytix, Inc.
• Locus Biosciences
• Micreos Human Health
• Nextbiotics
• OmniPhage
• Phagelux Inc.
• Pherecydes Pharma
• Phico Therapeutics Ltd.
• TechnoPhage SA
• TAILF Therapeutics
• The Eliava Foundation
• VyPhI, Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Phage Therapy - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Threat of Antibiotic Resistance Propels Demand for Alternative Antibacterial Therapies
  • Growing Clinical Validation of Phage Therapy Strengthens the Business Case for Targeted Bacteriophage Solutions
  • Increased Investment in Precision Medicine Expands the Addressable Market for Customized Phage Treatments
  • Regulatory Pathway Reforms and Compassionate Use Programs Throw the Spotlight on Phage-Based Therapeutics
  • Advancements in Genomic Sequencing and Synthetic Biology Drive Innovation in Next-Generation Phage Platforms
  • Outbreaks of Multidrug-Resistant Infections Accelerate Interest in Emergency and Hospital-Based Phage Applications
  • Establishment of Phage Banks and Libraries Supports Scalable, On-Demand Therapeutic Development
  • Integration with AI and Machine Learning Enables Faster Identification and Matching of Phages to Pathogens
  • Growing Acceptance of Microbiome Modulation Throws the Spotlight on Phages as Precision Modifiers
  • Expansion of Phage Therapy Trials Beyond Infectious Diseases Generates Opportunities in Oncology and Dermatology
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Phage Therapy Market Analysis of Annual Sales in US$ for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Phage Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 3: World 6-Year Perspective for Phage Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
  • TABLE 4: World Recent Past, Current & Future Analysis for Escherichia Coli by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 5: World 6-Year Perspective for Escherichia Coli by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 6: World Recent Past, Current & Future Analysis for Staphylococcus Aureus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 7: World 6-Year Perspective for Staphylococcus Aureus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Salmonella by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 9: World 6-Year Perspective for Salmonella by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 10: World Recent Past, Current & Future Analysis for Other Products by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 11: World 6-Year Perspective for Other Products by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 12: World Recent Past, Current & Future Analysis for Animal Health Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 13: World 6-Year Perspective for Animal Health Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Food Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 15: World 6-Year Perspective for Food Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
  • TABLE 16: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 17: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Phage Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 18: USA Recent Past, Current & Future Analysis for Phage Therapy by Product - Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 19: USA 6-Year Perspective for Phage Therapy by Product - Percentage Breakdown of Value Sales for Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products for the Years 2025 & 2030
  • TABLE 20: USA Recent Past, Current & Future Analysis for Phage Therapy by Application - Animal Health Application, Food Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 21: USA 6-Year Perspective for Phage Therapy by Application - Percentage Breakdown of Value Sales for Animal Health Application, Food Application and Other Applications for the Years 2025 & 2030
• CANADA
  • TABLE 22: Canada Recent Past, Current & Future Analysis for Phage Therapy by Product - Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 23: Canada 6-Year Perspective for Phage Therapy by Product - Percentage Breakdown of Value Sales for Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products for the Years 2025 & 2030
  • TABLE 24: Canada Recent Past, Current & Future Analysis for Phage Therapy by Application - Animal Health Application, Food Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 25: Canada 6-Year Perspective for Phage Therapy by Application - Percentage Breakdown of Value Sales for Animal Health Application, Food Application and Other Applications for the Years 2025 & 2030
• JAPAN
  • Phage Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 26: Japan Recent Past, Current & Future Analysis for Phage Therapy by Product - Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 27: Japan 6-Year Perspective for Phage Therapy by Product - Percentage Breakdown of Value Sales for Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products for the Years 2025 & 2030
  • TABLE 28: Japan Recent Past, Current & Future Analysis for Phage Therapy by Application - Animal Health Application, Food Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 29: Japan 6-Year Perspective for Phage Therapy by Application - Percentage Breakdown of Value Sales for Animal Health Application, Food Application and Other Applications for the Years 2025 & 2030
• CHINA
  • Phage Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 30: China Recent Past, Current & Future Analysis for Phage Therapy by Product - Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 31: China 6-Year Perspective for Phage Therapy by Product - Percentage Breakdown of Value Sales for Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products for the Years 2025 & 2030
  • TABLE 32: China Recent Past, Current & Future Analysis for Phage Therapy by Application - Animal Health Application, Food Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 33: China 6-Year Perspective for Phage Therapy by Application - Percentage Breakdown of Value Sales for Animal Health Application, Food Application and Other Applications for the Years 2025 & 2030
• EUROPE
  • Phage Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 34: Europe Recent Past, Current & Future Analysis for Phage Therapy by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
  • TABLE 35: Europe 6-Year Perspective for Phage Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
  • TABLE 36: Europe Recent Past, Current & Future Analysis for Phage Therapy by Product - Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 37: Europe 6-Year Perspective for Phage Therapy by Product - Percentage Breakdown of Value Sales for Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products for the Years 2025 & 2030
  • TABLE 38: Europe Recent Past, Current & Future Analysis for Phage Therapy by Application - Animal Health Application, Food Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Europe 6-Year Perspective for Phage Therapy by Application - Percentage Breakdown of Value Sales for Animal Health Application, Food Application and Other Applications for the Years 2025 & 2030
• FRANCE
  • Phage Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 40: France Recent Past, Current & Future Analysis for Phage Therapy by Product - Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 41: France 6-Year Perspective for Phage Therapy by Product - Percentage Breakdown of Value Sales for Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products for the Years 2025 & 2030
  • TABLE 42: France Recent Past, Current & Future Analysis for Phage Therapy by Application - Animal Health Application, Food Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 43: France 6-Year Perspective for Phage Therapy by Application - Percentage Breakdown of Value Sales for Animal Health Application, Food Application and Other Applications for the Years 2025 & 2030
• GERMANY
  • Phage Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 44: Germany Recent Past, Current & Future Analysis for Phage Therapy by Product - Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Germany 6-Year Perspective for Phage Therapy by Product - Percentage Breakdown of Value Sales for Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products for the Years 2025 & 2030
  • TABLE 46: Germany Recent Past, Current & Future Analysis for Phage Therapy by Application - Animal Health Application, Food Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 47: Germany 6-Year Perspective for Phage Therapy by Application - Percentage Breakdown of Value Sales for Animal Health Application, Food Application and Other Applications for the Years 2025 & 2030
• ITALY
  • TABLE 48: Italy Recent Past, Current & Future Analysis for Phage Therapy by Product - Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 49: Italy 6-Year Perspective for Phage Therapy by Product - Percentage Breakdown of Value Sales for Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products for the Years 2025 & 2030
  • TABLE 50: Italy Recent Past, Current & Future Analysis for Phage Therapy by Application - Animal Health Application, Food Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Italy 6-Year Perspective for Phage Therapy by Application - Percentage Breakdown of Value Sales for Animal Health Application, Food Application and Other Applications for the Years 2025 & 2030
• UNITED KINGDOM
  • Phage Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 52: UK Recent Past, Current & Future Analysis for Phage Therapy by Product - Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 53: UK 6-Year Perspective for Phage Therapy by Product - Percentage Breakdown of Value Sales for Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products for the Years 2025 & 2030
  • TABLE 54: UK Recent Past, Current & Future Analysis for Phage Therapy by Application - Animal Health Application, Food Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 55: UK 6-Year Perspective for Phage Therapy by Application - Percentage Breakdown of Value Sales for Animal Health Application, Food Application and Other Applications for the Years 2025 & 2030
• REST OF EUROPE
  • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Phage Therapy by Product - Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Rest of Europe 6-Year Perspective for Phage Therapy by Product - Percentage Breakdown of Value Sales for Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products for the Years 2025 & 2030
  • TABLE 58: Rest of Europe Recent Past, Current & Future Analysis for Phage Therapy by Application - Animal Health Application, Food Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 59: Rest of Europe 6-Year Perspective for Phage Therapy by Application - Percentage Breakdown of Value Sales for Animal Health Application, Food Application and Other Applications for the Years 2025 & 2030
• ASIA-PACIFIC
  • Phage Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 60: Asia-Pacific Recent Past, Current & Future Analysis for Phage Therapy by Product - Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 61: Asia-Pacific 6-Year Perspective for Phage Therapy by Product - Percentage Breakdown of Value Sales for Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products for the Years 2025 & 2030
  • TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Phage Therapy by Application - Animal Health Application, Food Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Asia-Pacific 6-Year Perspective for Phage Therapy by Application - Percentage Breakdown of Value Sales for Animal Health Application, Food Application and Other Applications for the Years 2025 & 2030
• REST OF WORLD
  • TABLE 64: Rest of World Recent Past, Current & Future Analysis for Phage Therapy by Product - Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 65: Rest of World 6-Year Perspective for Phage Therapy by Product - Percentage Breakdown of Value Sales for Escherichia Coli, Staphylococcus Aureus, Salmonella and Other Products for the Years 2025 & 2030
  • TABLE 66: Rest of World Recent Past, Current & Future Analysis for Phage Therapy by Application - Animal Health Application, Food Application and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
  • TABLE 67: Rest of World 6-Year Perspective for Phage Therapy by Application - Percentage Breakdown of Value Sales for Animal Health Application, Food Application and Other Applications for the Years 2025 & 2030

IV. COMPETITION